articleTop 1% cited

Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment

Clinical Cancer Research · 2009 · Vol. 15(8) · pp. 2920–2926

Carla M. Prado✉(University of Alberta)Vickie E. Baracos(University of Alberta)Linda J. McCargar(University of Alberta)Tony Reiman(Cancer Institute (WIA))Marina Mourtzakis(Cancer Institute (WIA))Katia Tonkin(Cancer Institute (WIA))John R. Mackey(Cancer Institute (WIA))Sheryl Koski(Cancer Institute (WIA))Edith Pituskin(Cancer Institute (WIA))Michael B. Sawyer(Cancer Institute (WIA))

View via DOI Publisher page

Abstract

Sarcopenia is a significant predictor of toxicity and TTP in metastatic breast cancer patients treated with capecitabine. Our results raise the potential use of body composition assessment to predict toxicity and individualize chemotherapy dosing.

Nutrition and Health in Aging Oral health in cancer treatment Cancer survivorship and careMedicineSarcopeniaCapecitabineBreast cancerInternal medicineOncologyMetastatic breast cancerToxicityAnthracyclineCancer

MeSH terms

CapecitabineAdultAgedAged, 80 and overAntimetabolites, AntineoplasticBody CompositionBreast NeoplasmsDeoxycytidineFemaleFluorouracilHumansMiddle AgedMuscular DiseasesNeoplasm MetastasisProspective Studies

Citations

1,092

FWCI

13.16

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by

Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index